...
首页> 外文期刊>Transplant infectious disease: an official journal of the Transplantation Society >A pharmacist‐driven antimicrobial stewardship intervention targeting cytomegalovirus viremia in ambulatory solid organ transplant recipients
【24h】

A pharmacist‐driven antimicrobial stewardship intervention targeting cytomegalovirus viremia in ambulatory solid organ transplant recipients

机译:在动态固体器官移植受者中靶向细胞瘤病毒病毒血症的药剂师驱动的抗微生物管道干预

获取原文
获取原文并翻译 | 示例

摘要

Abstract Background There is a growing need for robust antimicrobial stewardship interventions in both ambulatory and solid organ transplant (SOT) populations. Methods A retrospective quasi‐experiment was conducted to evaluate the impact of a pharmacist‐driven antimicrobial stewardship intervention targeting cytomegalovirus (CMV) viremia in ambulatory SOT recipients. The intervention consisted of (a) real‐time CMV DNA surveillance and result notification conducted by the pharmacist and (b) recommendations for the optimization of drug therapy provided at the time of result notification. The intervention period was compared to a pre‐intervention period of usual care. Of 431 adult SOT recipients who had an initial quantifiable CMV viral load in the ambulatory setting, 185 received antiviral induction therapy and were included for analysis. Results Significantly fewer patients in the intervention period reached a CMV viral load 10 000 IU/mL immediately prior to treatment (10.6% vs 27.3%; P = 0.004), and a significantly greater proportion of patients in the intervention period achieved CMV eradication at 21 days (84.5% vs 71.7%; P = 0.038). Additional differences favoring the intervention period were antiviral initiation within 5 days of the first quantifiable CMV DNA (62.4% vs 55.0%; P = 0.02) and time‐to‐CMV eradication (25.5 vs 28.9 days; P = 0.003). Although not significant, there were also numerical reductions in CMV‐related hospital admissions (11.9% vs 19.0%; P = 0.188) and CMV disease (5.9% vs 12.0%; P = 0.151) during the intervention period, as well as fewer episodes of CMV resistance at 1‐year (2.3% vs 4.0%; P = 0.689). Conclusion Together, these findings suggest a potential role for pharmacist involvement in CMV surveillance and treatment optimization in ambulatory SOT recipients.
机译:抽象背景越来越需要在动态和固体器官移植(SOT)人口中的强大抗微生物管道干预措施。方法采用回顾性准实验,评价药剂师驱动的抗微生物管道干预靶向动态SOT受体中的患有细胞病毒(CMV)病毒血症的影响。干预由药剂师和(b)在结果通知时提供的药剂师和(b)建议进行的实时CMV DNA监测和结果通知组成。干预期与通常护理的前期前期进行比较。在431个成人SOT接受者中,在动态环境中具有初始可量化的CMV病毒载荷,185名接受抗病毒感应治疗,并被包括用于分析。结果较少较少的干预期患者达到CMV病毒载荷>在治疗前立即达到10 000IU / mL(10.6%vs27.3%; p = 0.004),并且在干预期中明显更大比例达到CMV根除在21天(84.5%vs 71.7%; p = 0.038)。有利于干预期的额外差异是在第一种量化CMV DNA的5天内的抗病毒引发(62.4%Vs 55.0%; p = 0.02)和时间至CMV根除(25.5 Vs 28.9天; P = 0.003)。虽然没有显着,但CMV相关的医院入院的数值减少(11.9%Vs 19.0%; p = 0.188)和CMV疾病(5.9%与12.0%; p = 0.151),以及较少的发作CMV抗性在1年(2.3%Vs 4.0%; P = 0.689)。结论在一起,这些研究结果表明药剂师参与CMV监测和治疗优化在车身SOT受体中的潜在作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号